Trials / Conditions / Familial Mediterranean Fever

Familial Mediterranean Fever

34 registered clinical trials studyying Familial Mediterranean Fever — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients NCT07517250	Novartis Pharmaceuticals	—
Not Yet Recruiting	AGE and CALLY Index in Familial Mediterranean Fever NCT07439341	Bursa City Hospital	—
Not Yet Recruiting	Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF NCT06981520	Hitit University	—
Recruiting	Outcomes of Inspiratory Muscle Training in FMF Adolescents NCT07129538	Cairo University	N/A
Recruiting	Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise NCT07130318	Cairo University	N/A
Recruiting	is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean NCT07130305	Cairo University	N/A
Active Not Recruiting	Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterrane NCT07128225	Sohag University	—
Completed	Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Fam NCT06697028	Istanbul University - Cerrahpasa	—
Recruiting	Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks NCT06338891	University of Palermo	—
Unknown	Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology NCT06033339	University Hospital, Montpellier	N/A
Active Not Recruiting	Physical Abilities of Teenagers With Familial Mediterranean Fever NCT06257342	Véronique Hentgen	—
Completed	A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Mi NCT06923124	Novartis Pharmaceuticals	—
Withdrawn	A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) NCT05448391	Aristea Therapeutics, Inc.	Phase 2
Unknown	Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings NCT05488561	Sohag University	N/A
Unknown	Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever NCT05596643	Marmara University	—
Unknown	Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever NCT06034795	Aristotle University Of Thessaloniki	—
Recruiting	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resis NCT05190991	R-Pharm International, LLC	Phase 2
Recruiting	Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 NCT04478409	Hospices Civils de Lyon	—
Completed	Central Sensitization in Familial Mediterranean Fever (FMF) NCT05177120	Marmara University	—
Active Not Recruiting	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Famil NCT05092776	R-Pharm International, LLC	Phase 2
Unknown	Effects of Online Aerobic Exercise Training and Physical Activity Counseling in Juvenile Familial Mediterranea NCT04724993	Istanbul University	N/A
Completed	A Diagnostic Test for Familial Mediterranean Fever NCT03747315	Hospices Civils de Lyon	—
Completed	Tocilizumab for the Treatment of Familial Mediterranean Fever NCT03446209	University Hospital Tuebingen	Phase 2
Completed	The Movement Imagery Ability in Patients With Familial Mediterranean Fever NCT04729218	Medipol University	—
Unknown	Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Medi NCT02175589	Rambam Health Care Campus	Phase 2
Completed	Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever NCT01705756	Sheba Medical Center	Phase 3
Completed	The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF NCT02602028	Saglik Bilimleri Universitesi Gulhane Tip Fakultesi	Phase 4
Completed	Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients NCT01075906	Mutual Pharmaceutical Company, Inc.	Phase 1
Completed	Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever NCT01088880	Novartis Pharmaceuticals	Phase 2
Terminated	Heat Intolerance in the Group of FMF Patients NCT01059279	Sheba Medical Center	—
Withdrawn	Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission NCT00323440	Sheba Medical Center	—
Completed	Rilonacept for Treatment of Familial Mediterranean Fever (FMF) NCT00582907	The Cleveland Clinic	Phase 2
Unknown	Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients NCT00658060	Sheba Medical Center	—
Completed	Interleukin-1 Trap to Treat Autoinflammatory Diseases NCT00094900	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2